These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 27157128)

  • 21. Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera.
    Vella C; Ferguson M; Dunn G; Meloen R; Langedijk H; Evans D; Minor PD
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2603-7. PubMed ID: 7506299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
    Revilla A; Delgado E; Christian EC; Dalrymple J; Vega Y; Carrera C; González-Galeano M; Ocampo A; de Castro RO; Lezaún MJ; Rodríguez R; Mariño A; Ordóñez P; Cilla G; Cisterna R; Santamaría JM; Prieto S; Rakhmanova A; Vinogradova A; Ríos M; Pérez-Álvarez L; Nájera R; Montefiori DC; Seaman MS; Thomson MM
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):889-901. PubMed ID: 21226626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.
    Ye L; Sun Y; Lin J; Bu Z; Wu Q; Jiang S; Steinhauer DA; Compans RW; Yang C
    Virology; 2006 Aug; 352(1):74-85. PubMed ID: 16725170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of sCD4 on the binding and accessibility of HIV-1 gp41 MPER epitopes to human monoclonal antibodies.
    Peachman KK; Wieczorek L; Polonis VR; Alving CR; Rao M
    Virology; 2010 Dec; 408(2):213-23. PubMed ID: 20961591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The complex antigenicity of a small external region of the C-terminal tail of the HIV-1 gp41 envelope protein: a lesson in epitope analysis.
    Dimmock NJ
    Rev Med Virol; 2005; 15(6):365-81. PubMed ID: 16106492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.
    Eckhart L; Raffelsberger W; Ferko B; Klima A; Purtscher M; Katinger H; Rüker F
    J Gen Virol; 1996 Sep; 77 ( Pt 9)():2001-8. PubMed ID: 8810996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of natural polymorphism within the gp41 cytoplasmic tail of human immunodeficiency virus type 1 on the intracellular distribution of envelope glycoproteins and viral assembly.
    Lambelé M; Labrosse B; Roch E; Moreau A; Verrier B; Barin F; Roingeard P; Mammano F; Brand D
    J Virol; 2007 Jan; 81(1):125-40. PubMed ID: 17050592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
    Zwick MB; Jensen R; Church S; Wang M; Stiegler G; Kunert R; Katinger H; Burton DR
    J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope.
    Wilson C; Reitz MS; Aldrich K; Klasse PJ; Blomberg J; Gallo RC; Robert-Guroff M
    J Virol; 1990 Jul; 64(7):3240-8. PubMed ID: 2352323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unique functional properties of conserved arginine residues in the lentivirus lytic peptide domains of the C-terminal tail of HIV-1 gp41.
    Kuhlmann AS; Steckbeck JD; Sturgeon TJ; Craigo JK; Montelaro RC
    J Biol Chem; 2014 Mar; 289(11):7630-40. PubMed ID: 24497632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail.
    Wyss S; Dimitrov AS; Baribaud F; Edwards TG; Blumenthal R; Hoxie JA
    J Virol; 2005 Oct; 79(19):12231-41. PubMed ID: 16160149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 escape from the entry-inhibiting effects of a cholesterol-binding compound via cleavage of gp41 by the viral protease.
    Waheed AA; Ablan SD; Roser JD; Sowder RC; Schaffner CP; Chertova E; Freed EO
    Proc Natl Acad Sci U S A; 2007 May; 104(20):8467-71. PubMed ID: 17483482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions.
    Neurath AR; Strick N; Lin K; Jiang S
    AIDS Res Hum Retroviruses; 1995 Jun; 11(6):687-96. PubMed ID: 7576928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution.
    Shen X; Dennison SM; Liu P; Gao F; Jaeger F; Montefiori DC; Verkoczy L; Haynes BF; Alam SM; Tomaras GD
    Proc Natl Acad Sci U S A; 2010 Mar; 107(13):5972-7. PubMed ID: 20231447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Properties of a neutralizing antibody that recognizes a conformational form of epitope ERDRD in the gp41 C-terminal tail of human immunodeficiency virus type 1.
    Cleveland SM; Jones TD; Dimmock NJ
    J Gen Virol; 2000 May; 81(Pt 5):1251-60. PubMed ID: 10769067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody neutralization and escape by HIV-1.
    Wei X; Decker JM; Wang S; Hui H; Kappes JC; Wu X; Salazar-Gonzalez JF; Salazar MG; Kilby JM; Saag MS; Komarova NL; Nowak MA; Hahn BH; Kwong PD; Shaw GM
    Nature; 2003 Mar; 422(6929):307-12. PubMed ID: 12646921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 resistance to neutralizing antibodies: Determination of antibody concentrations leading to escape mutant evolution.
    Magnus C; Reh L; Trkola A
    Virus Res; 2016 Jun; 218():57-70. PubMed ID: 26494166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy.
    Ouyang Y; Yin Q; Li W; Li Z; Kong D; Wu Y; Hong K; Xing H; Shao Y; Jiang S; Ying T; Ma L
    Sci Rep; 2017 Jul; 7(1):6222. PubMed ID: 28740221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conserved positive selection signals in gp41 across multiple subtypes and difference in selection signals detectable in gp41 sequences sampled during acute and chronic HIV-1 subtype C infection.
    Bandawe GP; Martin DP; Treurnicht F; Mlisana K; Karim SS; Williamson C;
    Virol J; 2008 Nov; 5():141. PubMed ID: 19025632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An antibody specific for the C-terminal tail of the gp41 transmembrane protein of human immunodeficiency virus type 1 mediates post-attachment neutralization, probably through inhibition of virus-cell fusion.
    Heap CJ; Reading SA; Dimmock NJ
    J Gen Virol; 2005 May; 86(Pt 5):1499-1507. PubMed ID: 15831963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.